Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- I-Mab (NASDAQ:IMAB) has announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients with severe COVID-19.
- Plonmarlimab is designed to target human granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that plays a critical role in acute and chronic inflammation.
- The interim analysis showed positive preliminary results in mechanical ventilation-free (MVF) patients at baseline (N=91).
- Plonmarlimab treatment resulted in a higher MVF rate (83.6% vs. 76.7%), lower mortality rate (4.9% vs. 13.3%), higher recovery rates (68.9% vs. 56.7%) at day 14, and 80.3% vs. 70.0% at day 30, compared to placebo.
- The GM-CSF antibody also reduced time to recovery and hospitalization duration, as compared to placebo.
- The magnitudes of the clinical improvements were comparable to Humanigen Inc's (NASDAQ: HGEN) lenzilumab in a similar patient population.
- Biomarker results indicated that patients treated with plonmarlimab had reduced plasma levels of pro-inflammatory cytokines and chemokines critically involved in CRS, excluding not interferon-gamma.
- Plonmarlimab was well tolerated in all patients with no significant safety concerns.
- Price Action: IMAB shares are down 8.01% at $72.05 during the premarket session on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!